MCA stability tool

Check whether tablets and capsules are suitable for a multi-compartment compliance aid (MCA), and build a list to print.

Browse medicines A to Z

A (medicines beginning with A) B (medicines beginning with B) C (medicines beginning with C) D (medicines beginning with D) E (medicines beginning with E) F (medicines beginning with F) G (medicines beginning with G) H (medicines beginning with H) I (medicines beginning with I) K (medicines beginning with K) L (medicines beginning with L) M (medicines beginning with M) N (medicines beginning with N) O (medicines beginning with O) P (medicines beginning with P) Q (medicines beginning with Q) R (medicines beginning with R) S (medicines beginning with S) T (medicines beginning with T) U (medicines beginning with U) V (medicines beginning with V) W (medicines beginning with W) X (medicines beginning with X) Y (medicines beginning with Y) Z (medicines beginning with Z)

Medicines beginning with T

Tetrabenazine

Tetrabenazine 25mg tablets

No stability information

Stability notes for Tetrabenazine 25mg tablets

There are no stability notes for this medicine.

Suppliers (8) of Tetrabenazine 25mg tablets
Tetrabenazine 25mg tablets (A A H Pharmaceuticals Ltd)
Tetrabenazine 25mg tablets (Alliance Healthcare (Distribution) Ltd)
Tetrabenazine 25mg tablets (Aristo Pharma Ltd)
Tetrabenazine 25mg tablets (pharmaand GmbH)
Tetrabenazine 25mg tablets (Sun Pharma UK Ltd)
Tetrabenazine 25mg tablets (Tillomed Laboratories Ltd)
Tetrabenazine 25mg tablets (Zydus Pharmaceuticals UK Ltd)
Xenazine 25 tablets (Alliance Pharmaceuticals Ltd)

What the ratings mean

Compatible
Suitable for use. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label.
Use with caution
Suitable with mitigations. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label and supported by limited data.
Incompatible
Medicines under this category are not suitable for use in MCAs.
No stability information
These medicines have not been reviewed by SPS.